Pimecrolimus in the clinical practice of a dermatologist

Chronic inflammatory skin diseases are accompanied by the development of objective and subjective symptoms, which are manifested by erythema, edema, infiltration, accompanied by itching of varying severity. The goal of treatment of chronic skin diseases is resolution of objective symptoms and reduction of subjective complaints. Currently, the stages of treatment of varying degrees of severity of chronic dermatoses are defined. Topical glucocorticosteroids are traditionally used in treatment, which have a pronounced anti-inflammatory, immunosuppressive, antiproliferative effect, but the presence of side effects limits their use. In clinical practice, topical calcineurin inhibitors are successfully used, which, along with topical glucocorticosteroids, have an anti-inflammatory effect, reduce the intensity of itching. This article discusses the possible use of pimecrolimus cream 1% in atopic dermatitis and chronic dermatoses (off-label): psoriasis, squamous lichen, rosacea, lupus erythematosus, focal scleroderma, vitiligo, mastocytosis. Pimecrolimus 1% is administered to patients of different age groups in areas with thin sensitive skin, increased resorption capacity, on mucous membranes. Long-term use of pimecrolimus 1% both as a monotherapeutic agent and in combination with other external medications is safe, allows to stop objective and subjective clinical symptoms of diseases, gives an opportunity to use it as a proactive therapy. Long-term clinical studies confirm the safety of the use and long-term use of pimecrolimus cream 1% in different age groups and at different lesion areas. The use of pimecrolimus in skin and mucosal lesions is very promising. Long study of the drug in various dermatoses in different age groups proves its effectiveness and safety.

1. Ahn D., Robinson C.A. Pimecrolimus. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK545135/.

2. Rodriguez-Cerdeira C., Sanchez-Blanco E., Molares-Vila A. Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases. Mediators Inflamm. 2012:563709. https://doi.org/10.1155/2012/563709.

3. Efendieva K., Levina Yu., Namazova-Baranova L. Effectiveness and safety of 1% pimecrolimus cream as applied among children with atopic dermatitis. Pediatric Pharmacology. 2009;6(1):30-36. (In Russ.) Available at: https://www.pedpharma.ru/jour/article/view/1040.

4. Monakhov K., Ochelenko S. Effectiveness and safety of pimecrolimus in treatment of atopic dermatitis in children and adolescents. Current Pediatrics. 2008;7(6):141-144. (In Russ.) Available at: https://vsp.spr-journal.ru/jour/article/view/1495.

5. Murashkin N.N., Ivanov R.A., Ambarchian E.T., Epishev R.V., Materikin A.I., Opryatin L.A., Savelova A.A. Substantiation of Using Pimecrolimus 1% Cream in Proactive Therapy of Children with Atopic Dermatitis. Current Pediatrics. 2021;20(5):376-382. (In Russ.) https://doi.org/10.15690/vsp.v20i5.2310.

6. Pimecrolimus for the Treatment of Adults With Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review. In: CADTH Report / Project in Briefs. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017. Available at: https://www.ncbi.nlm.nih.gov/books/NBK481570/.

7. Torsekar R., Gautam M.M. Topical Therapies in Psoriasis. Indian Dermatol Online J. 2017;8(4):235-245. https://doi.org/10.4103/2229-5178.209622.

8. Mansouri P., Farshi S. Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J. 2006;12(2):7. https://doi.org/10.5070/D37c3542mx.

9. Arunkumar S., Kalappanavar A.N., Annigeri R.G., Kalappa S.G. Relative efficacy of pimecrolimus cream and triamcinolone acetonide paste in the treatment of symptomatic oral lichen planus. Indian J Dent. 2015;6(1):14-19. https://doi.org/10.4103/0975-962X.151692.

10. Ramirez J. Recurrent Facial Rash. Am Fam Physician. 2020;102(10):625-626. Available at: https://www.aafp.org/afp/2020/1115/p625.html.

11. Khondker L., Wahab M.A., Khan S.I. Efficacy of topical application of Pimecrolimus cream in the treatment of discoid lupus erythematosus. Mymensingh Med J. 2012;21(2):259-264. Available at: https://pubmed.ncbi.nlm.nih.gov/22561768/.

12. Lampropoulos C.E., D'Cruz D.P. Topical calcineurin inhibitors in systemic lupus erythematosus. Ther Clin Risk Manag. 2010;6:95-101. https://doi.org/10.2147/tcrm.s3193.

13. Raupov R.K., Kostik M.M. Juvenile Localized Scleroderma. Questions of Treatment. Current Pediatrics. 2020;19(3):228-234. (In Russ.) https://doi.org/10.15690/vsp.v19i3.2119.

14. Lee J.H., Kwon H.S., Jung H.M., Lee H., Kim G.M., Yim H.W., Bae J.M. Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019;155(8):929-938. https://doi.org/10.1001/jamadermatol.2019.0696.

15. Xu P., Chen J., Tan C., Lai R.S., Min Z.S. Pimecrolimus increases the melanogenesis and migration of melanocytes in vitro. Korean J Physiol Pharmacol. 2017;21(3):287-292. https://doi.org/10.4196/kjpp.2017.21.3.287.

16. Mashiah J., Harel A., Bodemer C., Hadj-Rabia S., Goldberg I., Sprecher E., Kutz A. Topical pimecrolimus for paediatric cutaneous mastocytosis. Clin Exp Dermatol. 2018;43(5):559-565. https://doi.org/10.1111/ced.13391.